Literature DB >> 6120774

Effects of cimetidine and ranitidine on hepatic drug metabolism.

K J Breen, R Bury, P V Desmond, M L Mashford, B Morphett, B Westwood, R G Shaw.   

Abstract

Cimetidine has been shown to impair elimination of a number of drugs metabolized by the hepatic mixed-function oxidase enzymes. It is uncertain whether this is related to its histamine H2-receptor antagonism or to its intrinsic structure. Ranitidine is a more potent H2-receptor antagonist and has a completely different structure. Cimetidine (1 gm/day for 7 days) induced a 23% and 35% fall in mean systemic clearance of antipyrine and theophylline, whereas ranitidine (300 mg/day 7 days) had no significant effect on the clearance of either drug. Our data suggest that the inhibition of drug metabolism by cimetidine is not related to histamine H2-receptor antagonism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6120774     DOI: 10.1038/clpt.1982.36

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  37 in total

1.  Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

Authors:  Kiyomi Ito; Koji Chiba; Masato Horikawa; Michi Ishigami; Naomi Mizuno; Jun Aoki; Yasumasa Gotoh; Takafumi Iwatsubo; Shin-ichi Kanamitsu; Motohiro Kato; Iichiro Kawahara; Kayoko Niinuma; Akiko Nishino; Norihito Sato; Yuko Tsukamoto; Kaoru Ueda; Tomoo Itoh; Yuichi Sugiyama
Journal:  AAPS PharmSci       Date:  2002

Review 2.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

3.  Drug interactions through binding to cytochrome p 450: the experience with h2-receptor blocking agents.

Authors:  U Klotz; I W Reimann
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

Review 4.  Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

Authors:  A H Price; R N Brogden
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

5.  The role of H2 receptor antagonist premedication in pregnant day care patients.

Authors:  J G Stock; A D Sutherland
Journal:  Can Anaesth Soc J       Date:  1985-09

Review 6.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

Review 7.  Theophylline poisoning. Pharmacological considerations and clinical management.

Authors:  P Gaudreault; J Guay
Journal:  Med Toxicol       Date:  1986 May-Jun

Review 8.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

9.  The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits.

Authors:  N L Harris; D E Brenner; L B Anthony; J C Collins; S Halter; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine.

Authors:  P K Honig; D C Wortham; K Zamani; D P Conner; J C Mullin; L R Cantilena
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.